CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Effect of montelukast on lung function and clinical symptoms in patients with cystic fibrosis.

  • Year: 2004
  • Date: 2004
  • Author: Stelmach I
Source

Pneumonol Alergol Pol. 2004;72(3-4):85-9.

Study design (if review, criteria of inclusion for studies)

20 week, placebo-controlled, and randomized, double blind, crossover trial

Participants

12 CF patients, aged 6-29

Interventions

montelukast or placebo

Outcome measures

At first and last week of each treatment course spirometry and whole body plethysmography parameters (FEV1, PEF, FEF25/75%, VC, TGV, Raw and RV) and clinical wheezing and cough scale were measured.

Main results

In montelukast group significant improvement in FEV1 (mean +/- SD, 54.6 +/- 22.6 before and 62 +/- 19.0 after treatment, p=0.0112) and FEF25/75% (28.9 +/- 23.0 before and 37.5 +/- 25.5 after treatment, p=0.0053) were observed. Compared with placebo montelukast significantly improved FEV1 (p=0.0032), PEF (p=0.0298) and FEF25/75% (p=0.0091). There was no significant difference in VC, TGV, Raw and RV. Montelukast compared with placebo significantly decreased cough (p<0.0001) and wheezing (p=0.0002) score.

Keywords: Adolescent; Adult; Anti-Bacterial Agents; Child; Leukotriene Antagonists; pharmacological_intervention; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Montelukast;